{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:59:06Z","timestamp":1788994746878,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s13555-025-01549-1","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:33:02Z","timestamp":1759894382000},"page":"3777-3792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of IL17\/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct07169682","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-9788","authenticated-orcid":false,"given":"Aikaterini","family":"Tsiogka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Soulaidopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Gregoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rompoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Panagakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Papoutsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Kostakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kontochristopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Vlachopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stratigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"Suppl 2","key":"1549_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","volume":"26","author":"K Reich","year":"2012","unstructured":"Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012;26(Suppl 2):3\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1549_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","volume":"11","author":"P Gisondi","year":"2020","unstructured":"Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:117.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1549_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jaad.2018.02.040","volume":"79","author":"B Lockshin","year":"2018","unstructured":"Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1549_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(13):1670\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1549_CR5","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00392-023-02291-4","volume":"113","author":"C Asenjo-Lobos","year":"2024","unstructured":"Asenjo-Lobos C, Gonz\u00e1lez L, Bulnes JF, Roque M, Mu\u00f1oz Venturelli P, Rodr\u00edguez GM. Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis. Clin Res Cardiol. 2024;113(2):246\u201359.","journal-title":"Clin Res Cardiol"},{"issue":"8","key":"1549_CR6","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U. The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(8):1695\u2013706.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1549_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835671","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zang J, Liu C, Yan Z, Shi D. Interleukin-17 links inflammatory cross-talks between comorbid psoriasis and atherosclerosis. Front Immunol. 2022;13:835671.","journal-title":"Front Immunol"},{"issue":"2","key":"1549_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000182256","volume":"218","author":"P Gisondi","year":"2009","unstructured":"Gisondi P, Fantin F, Del Giglio M, et\u00a0al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110\u20133.","journal-title":"Dermatology"},{"issue":"1","key":"1549_CR9","doi-asserted-by":"publisher","first-page":"21438","DOI":"10.1038\/s41598-021-00999-9","volume":"11","author":"H Kaiser","year":"2021","unstructured":"Kaiser H, Wang X, Kvist-Hansen A, et\u00a0al. Biomarkers of subclinical atherosclerosis in patients with psoriasis. Sci Rep. 2021;11(1):21438.","journal-title":"Sci Rep"},{"key":"1549_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.864185","volume":"9","author":"P Anyfanti","year":"2022","unstructured":"Anyfanti P, Margouta A, Goulas K, et\u00a0al. Endothelial dysfunction in psoriasis: an updated review. Front Med Lausanne. 2022;9:864185.","journal-title":"Front Med Lausanne"},{"issue":"13","key":"1549_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jacc.2009.10.061","volume":"55","author":"C Vlachopoulos","year":"2010","unstructured":"Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"1549_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.hjc.2021.04.005","volume":"63","author":"C Chasikidis","year":"2022","unstructured":"Chasikidis C, Oikonomou E, Lazaros G, et\u00a0al. Association of arterial stiffness with functional parameters in patients with systolic heart failure: data from the Corinthia study. Hellenic J Cardiol. 2022;63:86\u20138.","journal-title":"Hellenic J Cardiol"},{"issue":"24","key":"1549_CR13","first-page":"00117","volume":"S1109\u20139666","author":"R Xue","year":"2024","unstructured":"Xue R, Zhang J, Zhen Z, et\u00a0al. Estimated pulse wave velocity predicts mortality in patients with heart failure with preserved ejection fraction. Hellenic J Cardiol. 2024;S1109\u20139666(24):00117\u20139.","journal-title":"Hellenic J Cardiol"},{"key":"1549_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12872-016-0303-6","volume":"16","author":"M Wilenius","year":"2016","unstructured":"Wilenius M, Tikkakoski AJ, Tahvanainen AM, et\u00a0al. Central wave reflection is associated with peripheral arterial resistance in addition to arterial stiffness in subjects without antihypertensive medication. BMC Cardiovasc Disord. 2016;16:131.","journal-title":"BMC Cardiovasc Disord"},{"issue":"14","key":"1549_CR15","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1161\/CIRCULATIONAHA.105.535435","volume":"112","author":"C Vlachopoulos","year":"2005","unstructured":"Vlachopoulos C, Dima I, Aznaouridis K, et\u00a0al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112(14):2193\u2013200.","journal-title":"Circulation"},{"issue":"2","key":"1549_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s13555-024-01098-z","volume":"14","author":"H Kaiser","year":"2024","unstructured":"Kaiser H, N\u00e4slund-Koch C, Kvist-Hansen A, Skov L. Does systemic anti-psoriatic treatment impact the risk of cardiovascular disease? A review over cardiovascular imaging studies. Dermatol Ther (Heidelb). 2024;14(2):303\u201321.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1549_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1468-3083.2010.03947.x","volume":"25","author":"S Boehncke","year":"2011","unstructured":"Boehncke S, Salgo R, Garbaraviciene J, et\u00a0al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25(10):1187\u201393.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1549_CR18","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","volume":"141","author":"A Gonz\u00e1lez-Cantero","year":"2021","unstructured":"Gonz\u00e1lez-Cantero A, Ortega-Quijano D, \u00c1lvarez-D\u00edaz N, et\u00a0al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials. J Invest Dermatol. 2021;141(10):2402\u201311.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1549_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051934","volume":"12","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med. 2023;12(5):1934.","journal-title":"J Clin Med"},{"issue":"9","key":"1549_CR20","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1111\/jdv.12255","volume":"28","author":"H Montaudi\u00e9","year":"2014","unstructured":"Montaudi\u00e9 H, Albert-Sabonnadi\u00e8re C, Acquacalda E, et\u00a0al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2014;28(9):1186\u201391.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1549_CR21","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.ijcard.2013.07.025","volume":"168","author":"I Ikonomidis","year":"2013","unstructured":"Ikonomidis I, Ntai K, Kadoglou NP, et\u00a0al. The evaluation of pulse wave velocity using Arteriograph and Complior apparatus across multiple cohorts of cardiovascular-related diseases. Int J Cardiol. 2013;168(5):4890\u20132.","journal-title":"Int J Cardiol"},{"issue":"12 Pt 2","key":"1549_CR22","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1097\/00004872-199816121-00033","volume":"16","author":"IB Wilkinson","year":"1998","unstructured":"Wilkinson IB, Fuchs SA, Jansen IM, et\u00a0al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens. 1998;16(12 Pt 2):2079\u201384.","journal-title":"J Hypertens"},{"issue":"Pt 1","key":"1549_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1469-7793.2000.t01-1-00263.x","volume":"525","author":"IB Wilkinson","year":"2000","unstructured":"Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525(Pt 1):263\u201370.","journal-title":"J Physiol"},{"key":"1549_CR24","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1161\/CIRCULATIONAHA.105.535435","volume":"112","author":"C Vlachopoulos","year":"2005","unstructured":"Vlachopoulos C, Dima I, Aznaouridis K, et\u00a0al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112:2193\u2013200.","journal-title":"Circulation"},{"issue":"2","key":"1549_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines11020318","volume":"11","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka A, Gregoriou S, Stratigos A, et\u00a0al. The impact of treatment with IL-17\/IL-23 inhibitors on subclinical atherosclerosis in patients with plaque psoriasis and\/or psoriatic arthritis: a systematic review. Biomedicines. 2023;11(2):318.","journal-title":"Biomedicines"},{"issue":"3","key":"1549_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijcard.2011.06.112","volume":"151","author":"G Avgerinou","year":"2011","unstructured":"Avgerinou G, Tousoulis D, Siasos G, et\u00a0al. Anti-tumor necrosis factor \u03b1 treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol. 2011;151(3):382\u20133.","journal-title":"Int J Cardiol"},{"issue":"4","key":"1549_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","volume":"69","author":"H J\u00f3kai","year":"2013","unstructured":"J\u00f3kai H, Szakonyi J, Kont\u00e1r O, et\u00a0al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol. 2013;69(4):523\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1549_CR28","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/jdv.13649","volume":"30","author":"E Her\u00e9di","year":"2016","unstructured":"Her\u00e9di E, V\u00e9gh J, Pog\u00e1cs\u00e1s L, et\u00a0al. Subclinical cardiovascular disease and it\u2019s improvement after long-term TNF-\u03b1 inhibitor therapy in severe psoriatic patients. J Eur Acad Dermatol Venereol. 2016;30(9):1531\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1549_CR29","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/exd.14452","volume":"31","author":"J Wegner","year":"2022","unstructured":"Wegner J, Karbach S, Drosos I, et\u00a0al. TNF-\u03b1 blockade may lead to improvement of vascular function in psoriasis patients. Exp Dermatol. 2022;31(2):237\u201341.","journal-title":"Exp Dermatol"},{"issue":"8","key":"1549_CR30","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","volume":"137","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Harel F, Krueger JG, et\u00a0al. TNF-\u03b1 antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study. J Invest Dermatol. 2017;137(8):1638\u201345.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1549_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","volume":"39","author":"A Ortolan","year":"2021","unstructured":"Ortolan A, Ramonda R, Lorenzin M, et\u00a0al. Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol. 2021;39(1):158\u201361.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1549_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","volume":"140","author":"JM Gelfand","year":"2020","unstructured":"Gelfand JM, Shin DB, Alavi A, et\u00a0al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Investig Dermatol. 2020;140(1):85-93.e2.","journal-title":"J Investig Dermatol"},{"issue":"12","key":"1549_CR33","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","volume":"158","author":"JM Gelfand","year":"2022","unstructured":"Gelfand JM, Shin DB, Armstrong AW, et\u00a0al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial. JAMA Dermatol. 2022;158(12):1394\u2013403.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1549_CR34","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1111\/jdv.18830","volume":"37","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Thaci D, Ludwig RJ. The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: a large-scale global cohort study. J Eur Acad Dermatol Venereol. 2023;37(5):e683\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1549_CR35","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/bjd.14964","volume":"176","author":"W Rungapiromnan","year":"2017","unstructured":"Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890\u2013901.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1549_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jid.2011.304","volume":"132","author":"KB Gordon","year":"2012","unstructured":"Gordon KB, Langley RG, Gottlieb AB, et\u00a0al. A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis. J Investig Dermatol. 2012;132(2):304\u201314.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"1549_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000763","volume":"5","author":"B Champs","year":"2019","unstructured":"Champs B, Degbo\u00e9 Y, Barnetche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open. 2019;5(1):e000763.","journal-title":"RMD Open"},{"issue":"1","key":"1549_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2321194","volume":"35","author":"H Cho","year":"2024","unstructured":"Cho H, Kim YJ, Moon IJ, et\u00a0al. Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-\u03b1 and interleukin-12\/23 inhibitors: a nationwide population-based cohort study in Korea. J Dermatol Treat. 2024;35(1):2321194.","journal-title":"J Dermatol Treat"},{"issue":"5","key":"1549_CR39","volume":"16","author":"R Ni","year":"2024","unstructured":"Ni R, Zheng J, Varghese J, Kumar B. The impact of interleukin-17 inhibitors on major adverse cardiovascular events in psoriasis or psoriatic arthritis patients naive to biologic agents: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2024;16(5):e60980.","journal-title":"Cureus"},{"key":"1549_CR40","doi-asserted-by":"publisher","first-page":"1349636","DOI":"10.3389\/fimmu.2024.1349636","volume":"15","author":"L Ding","year":"2024","unstructured":"Ding L, Chen C, Yang Y, Zhang X. Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data. Front Immunol. 2024;15:1349636.","journal-title":"Front Immunol"},{"key":"1549_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.131819","volume":"402","author":"Z Al-Yafeai","year":"2024","unstructured":"Al-Yafeai Z, Sondhi M, Vadlamudi K, et\u00a0al. Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS). Int J Cardiol. 2024;402:131819.","journal-title":"Int J Cardiol"},{"key":"1549_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/VHRM.S464471","volume":"20","author":"H Mehta","year":"2024","unstructured":"Mehta H, Narang T, Dogra S, Handa S, Hatwal J, Batta A. Cardiovascular considerations and implications for treatment in psoriasis: an updated review. Vasc Health Risk Manag. 2024;20:215\u201329.","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"1549_CR43","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et\u00a0al. Euroguiderm guideline on the systemic treatment of Psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1549_CR44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/jdv.16926","volume":"35","author":"A Nast","year":"2021","unstructured":"Nast A, Smith C, Spuls PI, et\u00a0al. Euroguiderm guideline on the systemic treatment of Psoriasis vulgaris\u2014part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281\u2013317.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01549-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T10:03:01Z","timestamp":1763200981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1549"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01549-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stamatios Gregoriou is an Editorial Board member of Dermatology and Therapy. Stamatios Gregoriou was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Aikaterini Tsiogka, Stergios Soulaidopoulos, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos and Dimitrios Rigopoulos declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Andreas Syggros Hospital\u2019s ethics committee (AP 3610\/20-05-2021). The study was performed in accordance with the Helsinki Declaration of 1964, all subjects provided informed consent to participate in the study and for publication of their data. A retrospective study registration at Clinicaltrials.gov was performed to pursue publication of valuable research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}